Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

2023 International Day of Immunology

February 23, 2023

IUIS celebrates the International Day of Women and Girls in Science on February 11

February 9, 2023

IUIS-FAIS-SANTHE-ISZ-Immuno-Zambia 2022

December 21, 2022Education Committee (EDU)

Funding Opportunity from IUIS and FOCIS for Young Immunologists from the Developing World

December 1, 2022Gender Equality Committee (GEC)

IUIS-GEC National Gender Equality Campaign – Competition4ideas

November 29, 2022Gender Equality Committee (GEC)

Results of the 2022-2025 Elections – Executive Committee and Council Members  

November 21, 2022

News from ICLAS – November Bulletin

November 17, 2022

IUIS ImmunoArgentina 2022 and 2nd Argentinean Spring Course In Advanced Immunology (ASCAI-II)

November 10, 2022Education Committee (EDU)

EDU/IUIS-BIS WORKSHOP 2022 Report – Flow cytometry: from basic principles to research applications

November 10, 2022Education Committee (EDU)